NeOnc Technologies Holdings, Inc. Common Stock (NTHI)vsBeiGene, Ltd. (ONC)
NTHI
NeOnc Technologies Holdings, Inc. Common Stock
$5.45
-16.02%
HEALTHCARE · Cap: $137.81M
ONC
BeiGene, Ltd.
$317.00
+1.17%
HEALTHCARE · Cap: $33.06B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 13360823% more annual revenue ($5.34B vs $39,990). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
NTHI
Avoid14
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NTHI.
Margin of Safety
+79.5%
Fair Value
$1717.18
Current Price
$317.00
$1400.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Trading at 8.1x book value
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NTHI
The strongest argument for NTHI centers on Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : NTHI
The primary concerns for NTHI are EPS Growth, Market Cap, Return on Equity.
Bear Case : ONC
The primary concerns for ONC are Price/Book, EPS Growth, Return on Equity. A P/E of 120.4x leaves little room for execution misses.
Key Dynamics to Monitor
NTHI profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (161M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 14/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NeOnc Technologies Holdings, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
NeOnc Technologies Holdings, Inc. is a forward-thinking biotechnology firm dedicated to revolutionizing cancer treatment through advanced immunotherapy and molecular medicine. With a strong pipeline of innovative product candidates targeting crucial unmet needs in oncology, the company is strategically positioned to reshape treatment paradigms and enhance patient outcomes. Its collaborative partnerships within the biopharmaceutical arena further bolster its capabilities in bringing therapeutic innovations to market, rendering NeOnc a compelling investment prospect within the burgeoning cancer therapeutics sector.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?